Cancer multi-omics
- Submission status
- Open
- Submission deadline
Cancer is not one disease. Rather, it is a collection of perhaps hundreds of entities with both common and distinct biological and genetic/genomic features. The complexity of human cancers has challenged the research and clinical communities for decades. However, the emergence of advanced next generation sequencing technologies, development of small animal avatars based on the genomic variants that are expressed in human cancers, and the accelerated development of pharmaceutical agents designed to target genomic, genetic and epigenetic alterations has led to an explosion of novel assays for early detection of relapse and remission, more precise diagnostics, and expansion of novel clinical trials. Recognition of the high prevalence of causal pathogenic variants in a range of ‘cancer genes’ has been associated with the need for more sensitive and specific predictors of tumor type and age of onset in those patients at genetic risk. Furthermore, the comprehensive nature of these rapidly evolving discoveries has also highlighted the disparities in access to innovative technologies in both well-resourced and under-resourced countries.
This Collection will provide insight into the wide-ranging research related to the impact of genome science on cancer prediction, diagnosis and therapies and offer a glimpse into future opportunities to integrate genomics into clinical standard-of-care.
This Collection supports and amplifies research related to SDG 3.
Editors
-
David Malkin, MD, FRCPC, FRSC
The Hospital for Sick Children, Toronto, Canada
-
Adam Shlien, PhD, FCCMG
The Hospital for Sick Children, Toronto, Canada
-
Elaine R. Mardis, PhD
Nationwide Children’s Hospital, Columbus, Ohio, USA The Ohio State University, Columbus, Ohio, USA
